166 related articles for article (PubMed ID: 37492473)
1. The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer.
Zeng Y; Wang J; Zhong X; Xiang Z; Yang T; Yu S; Dai Z; Xu N; Liu L
Front Oncol; 2023; 13():1199492. PubMed ID: 37492473
[TBL] [Abstract][Full Text] [Related]
2. Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.
Liu QQ; Sun HF; Yang XL; Chen MT; Liu Y; Zhao Y; Zhao YY; Jin W
Cancer Med; 2019 Jun; 8(6):2840-2857. PubMed ID: 31016890
[TBL] [Abstract][Full Text] [Related]
3. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
[TBL] [Abstract][Full Text] [Related]
4. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.
Hou L; Qiu M; Chen M; Li F; Li J; Deng S; Yang Y; Du Z; Yang H
Gland Surg; 2021 Jun; 10(6):1889-1898. PubMed ID: 34268073
[TBL] [Abstract][Full Text] [Related]
5. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
6. Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study.
Wang J; Luo T; Xiang ZZ; He MM; Zeng YY; Yang T; Wei XY; Yu S; Dai ZL; Xu NY; Tan CF; Liu L
JMIR Public Health Surveill; 2023 Jul; 9():e47110. PubMed ID: 37463020
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.
Wu SG; Zhang WW; Wang J; Dong Y; Sun JY; Chen YX; He ZY
Future Oncol; 2019 Feb; 15(5):507-516. PubMed ID: 30378451
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
Cai S; Zuo W; Lu X; Gou Z; Zhou Y; Liu P; Pan Y; Chen S
Front Oncol; 2020; 10():1729. PubMed ID: 33072554
[No Abstract] [Full Text] [Related]
9. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
Reid S; Haddad D; Tezak A; Weidner A; Wang X; Mautz B; Moore J; Cadiz S; Zhu Y; Zheng W; Mayer IA; Shu XO; Pal T
Breast Cancer Res Treat; 2021 Oct; 189(3):845-852. PubMed ID: 34331630
[TBL] [Abstract][Full Text] [Related]
10. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.
Wang C; Chen Z; Zhou Y; Huang W; Zhu H; Mao F; Lin Y; Zhang Y; Guan J; Cao X; Sun Q
Gland Surg; 2021 Mar; 10(3):943-952. PubMed ID: 33842238
[TBL] [Abstract][Full Text] [Related]
11. Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis.
Lorona NC; Malone KE; Li CI
Breast Cancer Res Treat; 2021 Dec; 190(3):549-558. PubMed ID: 34651254
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract][Full Text] [Related]
13. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study.
Gong Y; Liu YR; Ji P; Hu X; Shao ZM
Sci Rep; 2017 Mar; 7():45411. PubMed ID: 28345619
[TBL] [Abstract][Full Text] [Related]
14. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
[TBL] [Abstract][Full Text] [Related]
15. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
16. Tumor subtypes and survival in male breast cancer.
Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
[TBL] [Abstract][Full Text] [Related]
17. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
[TBL] [Abstract][Full Text] [Related]
18. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
19. HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer.
Ma Y; Jiao D; Zhang J; Lv M; Chen X; Liu Z
Oncologist; 2024 Mar; 29(3):e309-e318. PubMed ID: 37769330
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study.
Dai D; Zhong Y; Wang Z; Yousafzai NA; Jin H; Wang X
PeerJ; 2019; 7():e7252. PubMed ID: 31309004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
